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ABSTRACT 
Nowadays brain tumors remain as a significant cause of morbidity and mortality and are often treatment 
refractory. The grading of brain tumor has an important implication in clinical management. Currently, 
magnetic resonance spectroscopy (MRS) is an important modality in evaluating and grading brain tumors. 
The aim of this study is  evaluation of metabolites in the differentiation of brain tumors and  grading of brain 
gliomas using HMRS (proton magnetic resonance spectroscopy).The studies were performed using single 
voxel MRS ،3Tesla with pulse of sequence used for MRS was point resolved single volume spectroscopy 
(PRESS)with repetition time (TR) 1000-6000ms and echo time (TE) 36-136ms and The detected 
distinguished metabolites was included Choline (Cho), Creatin (Cr), and N-acetyl a aspartate (NAA), 
37cases had data which passed quality control. The Patient ages ranged from 7 To 81 years, 17 were male 
and 20 female.MRS data was processed using SYNGO software to give mean spectra and metabolite 
concentrations which were compared using min it a band SPSS. To test the primary hypothesis, univariate 
logistic regression was performed on each individual measured metabolite quantity. Significant differences 
were found in concentrations of key metabolites and Cho/NAA and Cho/Cr ratios using T-test and 
significance (P≤0.05). In the assessment of age rate and tumor grading, the malignancies of brain tumors did 
not correlate with patients’ ages as well as sexuality. MRS can detect subtle differences between low grade 
brain tumors in children and should form part of the clinical assessment of these tumors. 
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INTRODUCTION 
     Glioma is the most common type of primary 
brain tumors, and is grouped into four grades 
according to the WHO criteria, which 
Astrocyromas and Oligodendroglia’s, 
Glioblastoma Multiforme (GBM) or grade IV 
astrocytoma are among the most common and 
lethal adult malignant glioma tumors [1,2]. Brain 
tumors are the top reasons of the death and the 
outbreak of diseases among all types of children’s 
tumors and a new method is required improve the 
clinical management.Magnet Resonance 
Spectroscopy H
1
 (MRS) allows the ingressive 
measurement of the ting molecules density in the 
tumor tissue in order to present the clinical useful 
radiological biomarkers[3]. Since the regular 
MRS and other biomedical radiological methods 
let us identify and locate the tumor only vaguely, 
in order to diagnose the tumors, biopsies are 
usually required. Unfortunately, a large number of 
tumors may not be accessible for biopsy; 
therefore, grading tumors using MRS has the 
additional advantage of an ingressive diagnosis 
method. MRS H
1
 is a prominent method to 
evaluate the type and grade of tumor; it is also an 
important method to target and assess the reaction 
to a treatment [4]. MRS is increasingly used to 
evaluate the brain neoplasms. It indicates the 
biochemical and metabolic combinations of 
various types’ brain tumors [5]. MRS not only can 
show the unusual finding in almost 100% of the 
brain tumors, but is also useful in distinguishing 
the tumors and specifying the metabolic changes 
in line with the tumor growth, the level of 
malignancy and the reaction to the treatment [6]. 
The MRS finding of the brain tumors, 
 




demonstrate the increased Cho levels and the 
decreased level of the NAA compared to those in 
a normal brain which reflects the increased 
cellular tissues [7, 8]. Since tumors are 
heterogeneous with necrosis nucleus, aggressive 
developed margins from around the brain tissue, 
there seems to be a variety of spectra depending 
on the area which is sampled using MRS[9]. 
However, due to various toll, heterogenic, overlap 
among different type of tumors and the analyzing 
techniques, it is often difficult for physicians to 
merely use MRS for their diagnosis; therefore, 
MRS should be used as an auxiliary method and 
technique for diagnosis. 
The purpose of this study is to evaluate the Choline 
(Cho),Cratine (Cr), N-Acetil-Aspartat metabolites 
and also dreading human brain tumors based on the 
metabolite ratio of Cho/Cr and Cho/NAA in an 
unaggressive way.The advance in radiology allows 
investing gate the characteristics of the tissue in an 
unaggressive way which offers mores more 
significant insights compared to the ones being 
offered by the tumor biology in in vivo[10]. Thus, 
the aim of modern radiology is not only to offer an 
unaggressive histological diagnosis but also to 
improve the categorization of the tumors. Using 
MRS-H starts with anatomical images; so that, in 
order to determine the volume (VOI), spectra are 
required. In order to provide the spectrum, different 
techniques including single- or multi-voxel 
spectroscopy using short and long time Echos (TE) 
might be used. Each technique has some pros and 
cons; therefore, choosing the right technique for a 
specific purpose is of great importance, because it 
will lead to improved quality of the resulted [11, 
12].  
 
MATERIALS AND METHODS 
     Regarding the conditions and facilitation, in the 
present study, evaluation of the patient’s 
metabolites was conducted using single-Voxel 
Spectroscopy PERESS and an approximately long 
time of echo ranging from 36 to136 msec the 
replicating time ranging from 1000 to 6000 msec. 
Spectroscopy of the penitent’s has been done using 
a 3T-MRI (3T Siemens Symphony Magnetron) 
which was single-Voxel (PRESS) and contained a 
set of square coils as its transmitter and receiver 
bonds. Experientially, the VOI of the MRS were 
inserted into the toll. Brain normal tissue, 
structures full of liquid and the fat tissue in the 
scalp were ignored. Water suppression, which is a 
part of pre-processing stages, was done prior to 
spectroscopy. The pulse sequence used for MRS 
was PRESS- point single-volume spectroscopy 
with 1000 to 6000 ms (TR) replicating time and 36 
to 136 ms (TE) long-time echo. The voxel size was 
mostly 1.5*1.5*1.5 cm
3
 for single-Voxel and in 
some case it was 2*2*2 cm
3
. The matrix size was 
16*16*1 and the scope was 160*160*15 mm
3
. The 
obtained protocols for the clinical data were 
defined radiologically and his to pathologically in 
order to ensure the adaptability of the obtained 
data. 
For Choline (in 3.22ppm), Cratine (3.02 to 3.04 
ppm) and N-Acetil Aspartate (in 2.02 ppm) 
metabolites which are resonant in their 
characteristics, quantative analysis of the spectra 
were conducted. The peak data were recorded and 
used to calculate the Cho/NAA and Cho/Cr ratios. 
The resonance intensities of the metabolites were 
determined by fitting the peak points. When the 
resonance intensities of the metabolites reduced 
significantly and were not determined 
automatically, the peak points, using the graded 
scale of monitor or film. These valves were then 
put into Cho/NAA and Cho/Cr ratios. 
The statistic calculations of the MRS data were 
first processed by SYNGO software in terms of 
mean spectra and the metabolite densities. They 
were, then, compared using Minitab and SPSS19 
softwares. Diagrams were drawn using Excell. In 
order to test the main hypothesis, single-variable 
logistic regression was performed for each single 
measured value of metabolites. 
Cho/ANN and Cho/were compared between tumor 
levels using parameter analysis. Metabolite ratios 
were also compared between glioma cases. 
Statistically, in a ≤0.05 significant mean deviations 
were observed.It is not needed to purchase an 
exclusive unit for this purpose to conduct MRS. As 
long as the scope his sufficient power, the majority 
of available MRS systems re scope-powers are able 
to be used. In the present study, 3 T scope- power 
has been used. 
There is no additional preparation required for the 
patient. The patient has to remain immobile for 
around 4 minutes during sampling from every unit 
for single-Vexel spectroscopy. The general trend 
for the evaluation of the brain images as well as the 
 




sampling from each unit takes about 30 minutes. 
Evaluating tumors based on the charges of the 
density of the common metabolites in almost-long 
including Cho, Cr, NAA and also Cho/NAA& 
Cho/Cr was done. 
37 participants had the acceptable data for the 
quality control; 30 of them had brain tumors (20 
females and 17 males with their age ranging from 7 
to 81 years old and the mean age of 41.46± 2.78 
years old) and 7 out of 37 were normal with their 
age ranging from 38 to 51 years old (m males and 
4 females and the mean age of 44.57 ±3.44). The 
research process was conducted in a therapeutic- 
educational center of cancer. The sampling period 
was from November 2012 to late April 2013. The 
patients who had tumors were referred to 
departments. Also, patients expressed their 
conscious consents and their consents were 
confirmed by the hospital s ethical committee. 
 
RESULTS 
     The data gathered from statistical samples are 
illustrated in the following table. Each patient s age 
& gender is demonstrated in the column next to 
them. The mean metabolites of each person were 
calculated with the precision of 1.1000 in Field Of 
View (FOV) and the Cho/Cr and Cho/NAA ratios 
were also calculated and presented in tables 1 and 
2. Table 1 contains the patients mean metabolites 
and table 2 entails the metabolite density in control 
samples (the participants who had normal 
metabolite density).  In table 3, the metabolite and 
disease intensity ratios were demonstrated in terms 
of Cho/Cr and Cho/NAA metabolite ratios. 
 
Table 1. The findings related to the mean metabolite 
density in the statistical samples of the 30 patients.  
NO Age Sex Cho Cr NAA 
1 11 M 1.08850 0.70500 0.63475 
2 46 F 0.84977 0.52338 0.37483 
3 59 F 0.47270 0.17330 0.24190 
4 31 M 0.95314 0.34929 0.29700 
5 70 M 1.54667 0.58777 0.28103 
6 31 F 1.86200 1.05360 0.25695 
7 29 F 0.37869 0.27131 0.34904 
8 58 M 0.98725 0.30325 0.22875 
9 17 M 0.47633 0.75767 0.39133 
10 28 M 0.74175 0.40975 0.43850 
11 30 F 1.34250 0.79750 0.22743 
12 60 F 0.55600 0.41969 0.35888 
13 49 F 0.64080 0.48127 0.47267 
14 28 F 0.57942 0.17415 0.16693 
15 47 F 0.26031 0.20492 0.24269 
16 34 M 0.55380 0.35840 0.34870 
17 32 F 0.97415 0.34546 0.15298 
18 49 F 0.91045 0.38373 0.17825 
19 58 F 0.14459 0.17691 0.19364 
20 56 M 0.06610 0.03740 0.04445 
21 81 M 0.70200 0.26400 0.27228 
22 64 M 0.45891 0.36087 0.37725 
23 49 M 0.35754 0.25392 0.19861 
24 34 M 0.26065 0.24647 0.12879 
25 25 M 0.19838 0.37029 0.29950 
26 19 F 0.41146 0.46354 0.32002 
27 49 F 0.32853 0,48611 0.37251 
28 63 F 0.23490 0.14774 0.29449 
29 30 F 0.38313 0.26125 0.22111 




Table 2. Findings related to the density of the metabolites and the metabolite ratio in control samples. 
No Age Sex Cho Cr NAA Cho/NA
A 
Cho/Cr 
31 49 M 0.043 0.060 0.108 0.72 0.40 
32 43 F 0.077 0.088 0.087 0.88 0.89 
33 38 M 0.010 0.010 0.024 1.00 0.42 
34 40 F 0.041 0.036 0.052 1.14 0.79 
35 45 M 0.025 0.040 0.057 0.63 0.44 
36 51 F 0.080 0.095 0.155 0.84 0.52 










Table 3. Findings related to Cho/Cr and Cho/NAA 
metabolite rations in the statistical samples of the patients 
having tumors. 
NO Cho\NAA Cho\Cr Grade 
1 1.71 1.54 Low 
2 2.27 1.62 Low 
3 1.95 2.73 High 
4 3.21 2.73 High 
5 5.50 2.63 High 
6 7.25 1.77 High 
7 1.08 1.40 Low 
8 4.32 3.26 High 
9 1.22 0.63 Low 
10 1.69 1.81 Low 
11 5.90 1.68 High 
12 1.55 1.32 Low 
13 1.36 1.33 Low 
14 3.47 3.33 High 
15 1.07 1.27 Low 
16 1.59 1.55 Low 
17 6.37 2.82 High 
18 5.11 2.37 High 
19 0.75 0.82 Low 
20 1.49 1.77 Low 
21 2.58 2.66 High 
22 1.22 1.27 Low 
23 1.80 1.41 Low 
24 2.02 1.06 Low 
25 0.66 0.54 Low 
26 1.29 0.89 Low 
27 0.88 0.68 Low 
28 0.80 1.59 Low 
29 1.73 1.47 Low 
30 0.82 0.63 Low 
 
The question which arises during testing and 
comparing the means of a healthy & a patient 
statistical community (student test) was whether 
two calculated metabolic ratios indicate a 
significant difference between the means of a 
healthy and a patient statistical community or 
not?. In order to investigate this question, T-
student means Test was used. In this test, the zero 
hypotheses are that there is no significant 
difference between the means of the patient and 
leathery community and the opposite hypothesis 
puts emphasis on the existence of significance. If 
sig ≤ 0.05 the test will be valid & the mean is in 
the range of the low and the high limit which 
means the means differ significantly. The 
comparison between the two communities was 
conducted low-grade healthy- patients brain 
lumps. The results of T-student Test for the two 
independent groups & comparing their means 
indicate that the mean differences with 0.95 of the 
community are in the range of the recognized low 
& high limits, therefore, the zero hypothesis is 
rejected and there is a significant difference 
between the two metabolic ration in high and low-
grade patients and the healthy people. Figure one 
illustrates the color metabolic map and the HMRS 




Figure1. A: A color metabolic d woman: the Cho/NAA in 
the highest ratio equals 108 which are illustrated in red 
and the lowest one equals zero. Which is shown in blue? 
The color metabolic mab in FOV equals zero and the 
Vexel is exactly placed on the toll. B: the metabolic 
density diagram which is resulted from a single-Vexel 
MRS. The relative reduction of density in NAA equals 
0.167 & in Cho equals 0.323; the Cratine density equals 
0.0147, FOV: 0.0, VOX: 1121. 
 





    The findings of this research show that NAA 
density has changed in the range of 0.044-0.635 
with the mean of 0.13 0.2872.  Cr densities has 
changed from 0.37 to 1.054 with the mean of 
0.48± 0.38993 and the Cho density has changed 
from 0.066 to 1.862 with the mean of 0.184± 
0.63094. The increase in Cho/NAA was observed 
to be from 0.660 to 7.0250 with the mean of 
1.220± 2.4220 and that in Cho/Cr was observed to 
be from 0.540 to 3.330 with the mean of 0.627± 
1.6860 in the brain lumps. Also, in comparing the 
independent healthy community with the patient 
one, sig ≤ 0.05 and there found to be a significant 
difference between these two communities the 
results of this study are in line with Alger JR and 
et al findings in their 1990 study in which the 
Hydrogen (protein) spectroscopy was successfully 
verified for distinguishing malignant brain tumors 
from the normal brain tissue both in adult an in 
children[12]. In their study in 2009; Tina Young 
Puissant and et al, found that Cho signal has a 
linear connection with the cellular density 
(opposite to what is observed with the obvious 
proliferative index). Instead of proliferative index, 
Cho peak is higher in the center of neoplastic 
mass and decreases environmentally. Cho signal 
is always low in the necrosis areas [13]. In 
evaluating the metabolite densities, in the center 
of the lumps and it is clearly observable in the 
color metabolite map of some patients (figure 1). 
These increases are linearly related to the cellular 
density. Since galliumare naturally proof read 
which destroy the neurons and decrease the NAA, 
therefore, cells tend to be tumoral. In 2005, Colen 
and et al found the decrease of NAA of the whole 
brain to be higher than the main tumor in the 
patients suffering from glioma tumors. This 
significant de chine of NAA of the whole brain 
probably indicates the extensive penetration of the 
tumor in the seemingly-healthy brain in MRI[14]. 
In an MRS quantitative study in 2006; Stadtbauer 
and et al found a correlation between the 
percentage of the tumor penetration of the MRS-
guided biopsy samples and the changes of NAA, 
Cho and Cho/NAA ratios in the related 
Vexels[15]. In 2009, Soares DP, law found that 
the net density of NAA decreases with the tumor 
proliferative index, while the net Cho density and 
Cho/NAA ratio increases with that[16]. We had 
the same findings in our studies. In the cases 
where there was a high decrease of NAA in the 
patients’ metabolite density, it was revealed that 
these patients have high-rate glioma. 
The lumps with high-grade of malignancy (3-
grade anaplastic gallium and Multiforme 
Glioblestoma or 4-grade ones) contain higher Cho 
and lower NAA compared to the low-grade 
lumps. Increased cho is associated with 
duplication and cellular density. In a systemic 
study conducted by Tlolling Worth et al; in 2006, 
it was reported that MRS is able to precisely 
distinguish high and low grade glioma. However, 
grading gliomas using MRS is really expanded 
diverse. This expanded diversity might be the 
result of different methods as well as different 
metabolites which could not make a difference 
among statistical overlapping in various grades of 
tumor, significant Cho/Cr and Cho/NAA and the 
high CBV in the grading of the glioma[17].
 
Using MRS, Smith JK and et al (2008) and,Lee 
and et al (2000) have found that the brain tumors 
show the increased levels of Cho and the 
decreased levels of NAA compared to those in the 
normal brain and reflect the rise in cellular 
tissue[18,19]. Furthermore Licavcanva andet al 
(2005) discovered that the increase in Cho is the 
indicator of the change & transformation of the 
cellular membrane the Cho has its peak 
correlation with mitotic activity and the 
malignancy grade of the tumor, so that the total 
Cho increase is along with the development of the 
tumor[20]. Our finding in the present study is in 
accordance with theirs. Another change in brain 
tumors is NAA decrease.  
This metabolite is a nervous marker whose 
decrease demonstrates the destruction and 
displacement of the normal tissue. Lack of NAA 
in inter-axial tumor shows that either the source is 
somewhere outside the central nervous system 
(metastase) or that the tumor is so malignant that 
destroyed all the neurons in that area[21].  
On the other hand, Cr signal is a little capricious 
in brain tumors and changes according to the type 
and grade of the tumor. H-MRS a typical 
spectrum for a brain tumor has a high-level Cho, 
low NAA and a little change in cr. Our finding in 
the present study also indicates the same changes. 
 




Usually Cho increase is associated with an 
increase in the Cho/NAA or Cho/Cr ratios 
compared to its net density. Although estimating 
the net dandify of Cho, it is sensitive to several 
errors that are essential to hypothesize. Therefore, 
Cho/NAA and Cho/Cr ratios are more precise to 
study. Cho-increase is observed in all the 
neoplastic destruction. The Cho peak can help with 
the diagnosis, preventing its development as well 
as curing the tumor. This increase is due to its 
participation in the cellular membrane s turnover 
which reflects cellular multiplication. 
Spaminato and et al (2007) discovered that it might 
be possible that low-grade Oligodendroglioma 
signify the increased Cho whichinfect, imitate the 
high grade tumor. These low grade tumors have 
high cellular density but lack multiplication and are 
telliahic and necrosis [22]. Reviewing the previous 
related articles demonstrate that those differences 
regarded in the spectroscopy technique, such using 
TE and choosing a method to specify the 
metabolite ratios are considered to show the 
differences in Cho levels between low and high 
grade gliomas and also the low gread gliomas 
indicate lower levels of Cho than the high grade 
ones[23]. This difference is ever understood using 
various methods of Cho quantitative assessment 
the tumor proton MRS clinical applications in 
grading gliomas are still under study at this stage, it 
is really important to understand the fact that MRS 
is sensitive to metabolic changes. Clinically, it is 
not unusual to find some low grade glioma with 
very high Cho:Cr &Cho:NAA ratios or the reverse 
high grade glioma with lower Cho:Cr &Cho:NAA 
ratios which is in the first place, due to the 
expanded necrosis. There are some overlaps among 
tumors with different grades. This also might be 
attributed to the various uses of metabolite ratios 
rather than an absolute quantitative assessment for 
comparing the grades of glioma. 
CONCLUSION 
    In tumors, anytime the synthesis of the 
membrane and multiplication increase, Cho level 
increases too; while, NAA levels decline, because 
neurons & axons destroy and demolish. In 
addition, there is a decline in Cr levels in tumors 
because of the exhaustion and increase of lipids in 
necrosis. MRS metabolite ratios (Cho/Cr 
&Cho/NAA) can be applicable to grade and 
distinguish the tumors. 37 patients have been 
studied in terms of assessing their brain tumor 
metabolite. Among them, a comparison was 
conducted between 30 ones who showed NAA 
decrease and tumoral Cho increase and the other 7 
who showed normal metabolite density.  
They have also been studied in terms of tumor 
grading based on WHO grading system and 
Cho/NAA &Cho/Cr ratios were supposed to be the 
grading standards. 20 out of these 30 tumoral 
patients were low grade and the other 10 were high 
grade.  
The results of this study demonstrated that high 
grade gliomas have higher mean Cho/NAA 
&Cho/Cr ratios than the low grade ones. Based on 
the reported results from patient’smagmatic 
resonance spectroscopy and comparing them to the 
control samples, it can be said that the magnetic 
resonance spectroscopy is efficient in assessing 
brain tumor metabolites and grading the tumors; 
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